NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Exwannabe,

You write:

Quote:
________________________________________
18 months v 23 months
________________________________________


No. it was 18.5 months vs 20.0 months when measured from randomisation as all randomized trials do.

A slight plus for DCVax-L P3. Not much.

Nothing stands out as major population differences at a quick glance. But devil can be in the details ad it s not hard to find a difference that causes 1.5 year diff in mOS.

Also, if the cotrol arm of DCVax comes in at 18.5, then you have treatmet at 20.8, and that isvery possibly not stat sig (do not knwo w/o doing numbers).


I believe you are wrong here. Randomization was done following surgery.

Immunotherapy: Treatment schedule.

All patients received the first line standard therapy for GBM: surgery, radiotherapy, and chemotherapy (Temozolomide). Randomization was done following surgery; patients in the treatment arm who received Audencel as an add-on to the standard treatment underwent leukocyte apheresis within 7-14 days after surgery. The first 4 immunizations were administered in weeks 7-10. Six more immunizations were applied in between the 6 blocks of maintenance chemotherapy. After completion of that schedule, patients received boost immunizations every 3 months. The vaccine was applied intranodally; each vaccine aliquot of Audencel contained 1-5 x 106 DC. The immunization schedule continued unaltered even if patients suffered disease recurrence and Temozolomide was withdrawn and replaced with an alternative therapy such as Bevacizumab. Patients of both groups received supportive care for acute or chronic toxicity whenever indicated.
https://www.mdpi.com/2072-6694/10/10/372/s1